Primo Nery Lara, Jr., M.D. for UC Davis Health

Primo Nery Lara, Jr., M.D.

Director, UC Davis Comprehensive Cancer Center

Executive Associate Dean for Cancer Programs

Professor of Medicine

To see if Primo Nery Lara, Jr. is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).





Internal Medicine

Locations and Contact

2279 45th Street
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

I practice compassionate, evidence-based, and innovative care for people with cancer with the goal of improving their outcomes and quality of life.

Clinical Interests

Dr. Lara is a medical oncologist and clinician scientist who has expertise in genitourinary and thoracic malignancies. He is also an expert in cancer clinical trial design and conduct, having successfully led investigational trials from phase I to phase III.

Research/Academic Interests

Dr. Lara's research is focused on investigational new approaches to treat, control, or cure cancer of the genitourinary tract and lung.


Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.S., Biology, University of the Philippines, Quezon City, Philippines, 1987

Medical School

M.D., University of the Philippines College of Medicine, Manila, Philippines, 1992


Internal Medicine, Rush University, Chicago IL 1993-1994


Internal Medicine, Rush University, Chicago IL 1994-1996


Hematology-Oncology, UC Davis, Sacramento CA 1996-1999

Best Doctors, SacTown Magazine, 2021

Best Doctors, Sacramento Magazine, 2020

Named one of the nation's Best Doctors in Oncology, 2011-present (Best Doctors Inc./Sacramento Magazine), 2021

Sacramento Magazine’s Top 300 Most Powerful Business Leaders, 2019

Principal Investigator (current and past) on many funded research and training grants,

Abrahão R, Cooley JJP, Maguire FB, Parikh-Patel A, Morris CR, Schwarz EB, Wun T, Keegan THM. Stage at diagnosis and survival among adolescents and young adults with lymphomas following the Affordable Care Act implementation in California. Int J Cancer. 2022 Apr 1;150(7):1113-1122. doi:10.1002/ijc.33880. Epub 2021 Dec 8. PMID:34800045.

Tsamouri MM, Durbin-Johnson BP, Culp WTN, Palm CA, Parikh M, Kent MS, Ghosh PM. Untargeted Metabolomics Identify a Panel of Urinary Biomarkers for the Diagnosis of Urothelial Carcinoma of the Bladder, as Compared to Urolithiasis with or without Urinary Tract Infection in Dogs. Metabolites. 2022 Feb 24;12(3). doi:10.3390/metabo12030200. PMID:35323643.

Voon PJ, Chen EX, Chen HX, Lockhart AC, Sahebjam S, Kelly K, Vaishampayan UN, Subbiah V, Razak AR, Renouf DJ, Hotte SJ, Singh A, Bedard PL, Hansen AR, Ivy SP, Wang L, Stayner LA, Siu LL, Spreafico A. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. J Exp Clin Cancer Res. 2022 Feb 7;41(1):51. doi:10.1186/s13046-021-02236-7. PMID:35130943.

Chu JN, Stewart SL, Gildengorin G, Wong C, Lam H, McPhee SJ, Chen MS, Bastani R, Maxwell AE, Taylor VM, Nguyen TT. Effect of a media intervention on hepatitis B screening among Vietnamese Americans. Ethn Health. 2022 Feb;27(2):361-374. doi:10.1080/13557858.2019.1672862. Epub 2019 Oct 14. PMID:31608675.

Evans AC, Setzkorn T, Edmondson DA, Segelke H, Wilson PF, Matthay KK, Granger MM, Marachelian A, Haas-Kogan DA, DuBois SG, Coleman MA. Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. Radiat Res. 2022 Feb 1;197(2):101-112. doi:10.1667/RADE-20-00173.1. PMID:34673986.

Roussos Torres ET, Rafie C, Wang C, Lim D, Brufsky A, LoRusso P, Eder JP, Chung V, Downs M, Geare M, Piekarz R, Streicher H, Anforth L, Rudek MA, Zhu Q, Besharati S, Cimino-Mathews A, Anders RA, Stearns V, Jaffee EM, Connolly RM. Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clin Cancer Res. 2021 Nov 1;27(21):5828-5837. doi:10.1158/1078-0432.CCR-20-5017. Epub 2021 Jun 16. PMID:34135021.

Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM, Lara PN Jr. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clin Lung Cancer. 2021 Nov;22(6):541-548. doi:10.1016/j.cllc.2021.05.001. Epub 2021 May 15. PMID:34140248.

Tsamouri MM, Steele TM, Mudryj M, Kent MS, Ghosh PM. Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans. Biomedicines. 2021 Oct 14;9(10). doi:10.3390/biomedicines9101472. PMID:34680588.

Llorens-Agost M, Ensminger M, Le HP, Gawai A, Liu J, Cruz-García A, Bhetawal S, Wood RD, Heyer WD, Löbrich M. POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis. Nat Cell Biol. 2021 Oct;23(10):1095-1104. doi:10.1038/s41556-021-00764-0. Epub 2021 Oct 6. PMID:34616022.

For a comprehensive list of Dr. Lara's publications, please click here.